AbbVie, Teneobio to Develop Multiple Myeloma Treatment

Date : 02/11/2019 @ 1:46PM
Source : Dow Jones News
Stock : Abbvie Inc. (ABBV)
Quote : 78.8  1.19 (1.53%) @ 3:07PM

AbbVie, Teneobio to Develop Multiple Myeloma Treatment

AbbVie Inc. (NYSE:ABBV)
Historical Stock Chart

6 Months : From Dec 2018 to Jun 2019

Click Here for more AbbVie Inc. Charts.
   By Colin Kellaher 

AbbVie Inc. (ABBV) on Monday said it reached an agreement with privately held biotechnology company Teneobio Inc. and its TeneoOne Inc. affiliate to develop and commercialize TNB-383B for the potential treatment of multiple myeloma.

The North Chicago, Ill., biopharmaceutical company said it will make a $90 million upfront payment to TeneoOne, which will continue developing TNB-383B through phase 1.

AbbVie said it will have the exclusive right to acquire TeneoOne and lead subsequent global development and commercialization of the immunotherapeutic.

AbbVie said TeneoOne's shareholders would also be eligible for regulatory and commercial sales milestones should AbbVie exercises its acquisition rights.

AbbVie said Teneobio will begin the clinical program for TNB-383B in the first half of 2019.


Write to Colin Kellaher at


(END) Dow Jones Newswires

February 11, 2019 08:31 ET (13:31 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Latest ABBV Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.